News
Burrill & Company Announces Close of Burrill Brazil Fund I January 18, 2012 | Press Release
David Wetherell Joins Burrill & Company Venture Capital Group as Managing Director January 06, 2012 | Press Release
Global Financial Market Turmoil Overshadows Biotech Successes in 2011 January 03, 2012 | Press Release
See all News
Our Advisory Boards include some of the most respected professionals in the industry, including CEOs, Nobel laureates, and other industry luminaries.
- Burrill Life Sciences III Advisory Board
- Burrill Life Sciences II Advisory Board
- Burrill Biotechnology Advisory Board
- Burrill Agbio Advisory Board
- Burrill Nutraceuticals Advisory Board
Burrill Life Sciences III Advisory Board
Paul Berg—Cahill Professor in Biochemistry, Emeritus, Stanford University; Director, Emeritus, Beckman Center for Molecular and Genetic Medicine at Stanford; Nobel Laureate in Chemistry
Carl Feldbaum—President Emeritus, Biotechnology Industry Organization.
Frederick Frank—Vice Chairman and Director, Lehman Brothers.
Martin Gerstel—Chairman of Compugen, Keddem Bioscience and Evogene; Co-Chairman of Itamar Medical; former Co-Chairman and CEO of ALZA Corporation
Lee Hood—President of The Institute for Systems Biology
David M. Lawrence—Chairman and CEO (retired), Kaiser Foundation Health Plan and Hospitals
George Poste—Chief Scientist, Complex Adaptive Systems Initiative; Regents' Professor and Del E. Webb Distinguished Professor of Biology, Arizona State University, Skysong
Tommy Thompson—Former Secretary of Health & Human Services; former Governor of Wisconsin; BLSCF II Advisory Board
Burrill Life Sciences II Advisory Board
Paul Berg—Cahill Professor in Biochemistry, Emeritus, Stanford University; Director,
Emeritus, Beckman Center for Molecular and Genetic Medicine at Stanford; Nobel Laureate
in Chemistry
Sean Carroll—Investigator, Howard Hughes Medical Institute; Professor of Genetics, University
of Wisconsin, Madison
Jonathan Dordick—The Howard P. Isermann Professor in the Departments of Chemical and
Biological Engineering and Biology, Center for Biotechnology and Interdisciplinary Studies,
Rensselaer Polytechnic Institute
Alain Enthoven—Marriner S. Eccles Professor of Public and Private Management Emeritus at
the Stanford Graduate School of Business
Frederick Frank—Vice Chairman, Peter J. Solomon Company
Paul Freiman—President and CEO of Neurobiological Technologies; former Chairman and
CEO, Syntex
Martin Gerstel—Chairman of Compugen, Keddem Bioscience, and Evogene; Co-Chairman
of Itamar Medical; former Co-Chairman and CEO of ALZA Corporation
Jeff Goldsmith—President, Health Futures
David M. Lawrence—Chairman and CEO (retired), Kaiser Foundation Health Plan and
Hospitals
Eric Lander—Director, Broad Institute of MIT and Harvard
Ernest Mario, Ph.D.—Chairman, CEO of Capnia, Palo Alto, California. Capnia is a privately
held pharmaceutical company utilizing carbon dioxide as a therapeutic medical gas to treat migraine
and rhinitus.
George Poste—Chief Scientist, Complex Adaptive Systems Initiative; Regents' Professor and Del E. Webb Distinguished Professor of Biology, Arizona State University, Skysong
L. John Wilkerson—Founder of the Wilkerson Group, now an IBM Company; Managing Director
of Galen Partners, a late-stage healthcare private equity fund
Keith R. Yamamoto—Professor of Cellular and Molecular Pharmacology, Executive Vice Dean
in the School of Medicine at the University of California, San Francisco (UCSF)
Burrill Biotechnology Advisory Board
Paul Berg—Cahill Professor in Biochemistry, Emeritus, Stanford University; Director, Emeritus, Beckman Center for Molecular and Genetic Medicine at Stanford; Nobel Laureate in Chemistry
Sean Carroll—Investigator, Howard Hughes Medical Institute; Professor of Genetics, University
of Wisconsin, Madison
Frederick Frank—Vice Chairman and Director, Lehman Brothers
Paul Freiman—President and CEO of Neurobiological Technologies; former Chairman and
CEO, Syntex
Martin Gerstel—Chairman of Compugen, Keddem Bioscience, and Evogene; Co-Chairman of Itamar Medical; former Co-Chairman and CEO of ALZA Corporation
Jeff Goldsmith—President, Health Futures
Eric Lander—Director, Broad Institute of MIT and Harvard
Ernest Mario, Ph.D.—Chairman, CEO of Capnia, Palo Alto, California. Capnia is a privately held pharmaceutical company utilizing carbon dioxide as a therapeutic medical gas to treat migraine and rhinitus.
George Poste—Chief Scientist, Complex Adaptive Systems Initiative; Regents' Professor and Del E. Webb Distinguished Professor of Biology, Arizona State University, Skysong
L. John Wilkerson—Founder of the Wilkerson Group, now an IBM Company and currently
Managing Director of Galen Partners, a late stage healthcare private equity fund
Keith R. Yamamoto—Professor of Cellular and Molecular Pharmacology, Executive Vice Dean
in the School of Medicine at the University of California, San Francisco (UCSF)
Burrill Agbio Advisory Board
Charles Arntzen—President and CEO Emeritus, Boyce Thompson Institute for Plant Research; Regent’s Professor, Arizona Biodesign Institute, Arizona State University; member of President George W. Bush’s Council of Advisors on Science and Technology (PCAST)
Dennis Purcell—Senior Managing Director, Aisling Capital and Perseus-Soros Management, LLC; former Managing Director of Life Sciences Investment Banking, Chase Hambrecht & Quist
Marc Zabeau—CEO Methexis Genomics; Scientific Advisor, Department of Plant Systems Biology, Flemish Interuniversity Institute for Biotechnology

